Publikationen in Zusammenarbeit mit Forschern von Instituto Ramón y Cajal de Investigación Sanitaria (12)

2024

  1. e14a2 Transcript Favors Treatment-Free Remission in Chronic Myeloid Leukemia When Associated with Longer Treatment with Tyrosine Kinase Inhibitors and Sustained Deep Molecular Response

    Journal of Clinical Medicine, Vol. 13, Núm. 3

2022

  1. Tyrosine kinase inhibitor dose reduction during the management ofaccelerated phase chronic myeloid leukemia

    Leukemia Research

2021

  1. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs

    Blood, Vol. 138, Núm. 21, pp. 2031-2041

  2. Development and validation of a sequential two-step algorithm for the screening of individuals with potential polycythaemia vera

    Scientific Reports, Vol. 11, Núm. 1

  3. Poor outcome in patients with acute leukemia on intensive chemotherapy and COVID-19

    Bone Marrow Transplantation

  4. Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice

    Blood Cancer Journal

2020

  1. Clinico-biological characteristics of patients with myelofibrosis: an analysis of 1,000 cases from the Spanish Registry of Myelofibrosis

    Medicina Clinica, Vol. 155, Núm. 4, pp. 152-158

  2. Expert opinion—management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors

    Leukemia, Vol. 34, Núm. 6, pp. 1495-1502

  3. Natural history of polycythemia vera and essential thrombocythemia presenting with splanchnic vein thrombosis

    Annals of Hematology, Vol. 99, Núm. 4, pp. 791-798

2018

  1. Evaluation of resistance to HIV-1 infection ex vivo of PBMCs isolated from patients with chronic myeloid leukemia treated with different tyrosine kinase inhibitors

    Biochemical Pharmacology, Vol. 156, pp. 248-264

  2. Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients

    Blood Cancer Journal, Vol. 8, Núm. 10

2017

  1. Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: Results from the ENESTfreedom study

    Leukemia, Vol. 31, Núm. 7, pp. 1525-1531